Clinical Trial Update: Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

View source ↗

Summary

Observational program evaluating hospitalization rates for respiratory syncytial virus in high-risk children who received palivizumab prophylaxis; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: AbbVie | Conditions: Respiratory Syncytial Virus (RSV) | Status: COMPLETED | Results posted: 2016-06-28